Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.

US-Money-and-Pills_V2_1200x675

More from Drug Pricing

More from Scrip